Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Clifton

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Immunotherapy|June 5, 2014
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical responseErika J Schneble, John S Berry, Francois A Trappey, et al.
Expert Review of Clinical Immunology|June 21, 2016
Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccinesT J Vreeland, G T Clifton, G S Herbert, et al.
Human Vaccines|February 16, 2011
Folate receptor α: a storied past and promising future in immunotherapyGuy T Clifton, Alan K Sears, Kevin S Clive, et al.
Cancer|September 17, 2010
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Guy T Clifton, Ritesh Patil, et al.
The Journal of Surgical Research|February 26, 2022
Maximizing Benefit of Virtual Learning: Lessons From the Coronavirus Disease 2019 PandemicElizabeth L Carpenter, Alexandra M Adams, Robert C Chick, et al.
Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.
Obesity Surgery|January 30, 2023
Iatrogenic Inferior Vena Cava Injury in the Reoperative Foregut: a Technique for Minimally Invasive RepairElizabeth L Carpenter, Ashley N Flinn, David W Schechtman, et al.
Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.
Journal of Cancer|January 2, 2016
Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or ObservationJohn S Berry, Alfred F Trappey, Timothy J Vreeland, et al.
Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Immunotherapy|June 5, 2014
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical responseErika J Schneble, John S Berry, Francois A Trappey, et al.
Expert Review of Clinical Immunology|June 21, 2016
Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccinesT J Vreeland, G T Clifton, G S Herbert, et al.
Human Vaccines|February 16, 2011
Folate receptor α: a storied past and promising future in immunotherapyGuy T Clifton, Alan K Sears, Kevin S Clive, et al.
Cancer|September 17, 2010
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Guy T Clifton, Ritesh Patil, et al.
The Journal of Surgical Research|February 26, 2022
Maximizing Benefit of Virtual Learning: Lessons From the Coronavirus Disease 2019 PandemicElizabeth L Carpenter, Alexandra M Adams, Robert C Chick, et al.
Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.
Obesity Surgery|January 30, 2023
Iatrogenic Inferior Vena Cava Injury in the Reoperative Foregut: a Technique for Minimally Invasive RepairElizabeth L Carpenter, Ashley N Flinn, David W Schechtman, et al.
Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.
Journal of Cancer|January 2, 2016
Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or ObservationJohn S Berry, Alfred F Trappey, Timothy J Vreeland, et al.
Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.
Pageof 8